SCNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Scienture Holdings Inc (SCNX) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown significant revenue growth due to the FDA approval of Arbli, its financials remain weak with negative EPS and net income. Technical indicators suggest a bearish trend, and there are no strong trading signals or significant positive catalysts to justify an immediate investment. Holding off for now is recommended.
The stock shows a bearish trend with MACD below zero, negatively contracting. RSI is neutral at 29.297, and moving averages indicate a bearish setup (SMA_200 > SMA_20 > SMA_5). Key support is at 0.275, and resistance is at 0.469.
Analysts have initiated coverage with a Buy rating and a $1.50 price target.
Financials for Q4 2025 show a significant revenue drop (-417.80% YoY) and negative net income (-$28.12M). Technical indicators are bearish, and no recent congress trading data or insider/hedge fund activity suggests strong interest.
2025/Q4 financials show a revenue drop of -417.80% YoY to -$168,699. Net income improved to -$28.12M (up 292.59% YoY), and EPS increased to -1.51 (up 106.85% YoY). Gross margin improved significantly to 76.8%, up 1343.61% YoY.
Maxim initiated coverage with a Buy rating and a $1.50 price target on 2026-02-24.
